A phase I/II trial of intrathecal administration of recombinant human ARSA (rhASA) (NCT01510028), showed that after repeated injections in children with MLD, sulfatide and lysosulfatide levels in CSF decreased to normal, while the rate of motor decline slowed. The gene discussed is ARSA; the disease is metachromatic leukodystrophy.